The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Lymphoma tumor microenvironment influences toxicity after CD19 CAR-T
Michael Jain, MD, PhD, Moffitt Cancer Center, Tampa, FL, discusses his group’s investigation og whether the lymphoma tumor microenvironment influences toxicity after CD19 CAR-T. Results indicated that the incidence of severe toxicity following CD19 CAR T-cell therapy is influenced by baseline characteristics that are present prior to infusion, and that reducing systemic inflammation or encouraging T-cell infiltration prior to infusion are potential strategies for lowering the associated toxicity. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
